

Cost of Test

Artera will work with your insurance company to seek reimbursement for this test. If you have Medicare Fee For Service, there is an established payment rate and you should have no out-of-pocket costs.

If your out-of-pocket costs are greater than \$285, please contact Artera to learn more about available financial assistance programs.

Patients who have questions or wish not to have the test performed should contact Artera and a team member will respond to your inquiry.

How to Order

1.



Physician orders the test.

2.



Existing biopsy sample sent to our lab.

3.



Test results sent to ordering physician.

4.



Patient and physician review results together.

To learn more:

Visit artera.ai or scan the QR code




For general questions,
please contact:
info@artera.ai

For billing questions,
please contact:
billing@artera.ai
1-650-239-7018



ArteraAI Prostate Test



ArteraAI Prostate Test



Patients diagnosed with localized prostate cancer are faced with many treatment options and uncertainty about what is right for them.



Based on individual patient characteristics, the ArteraAI Prostate Test can provide insight into the following:


- Risk of developing distant metastasis
- Risk of prostate cancer-specific mortality
- Active surveillance as a suitable option^a
- Reduction in risk of distant metastasis by adding short-term androgen deprivation therapy to radiation therapy^b

The ArteraAI Prostate Test can help determine the best cancer treatment plan.


^aFor patients with NCCN very low-, low-, or favorable-intermediate risk.

^bFor patients with NCCN intermediate-risk.

How it Works



Sample Test Results



1 Prognostic Risk

This biomarker explains the cancer's aggressiveness, presented as the risk of distant metastasis at 10 years.

2 Active Surveillance Insights

For men with lower risk^a prostate cancer, the likelihood of the patient's cancer showing more aggressive features in the future is compared to other patients managed with active surveillance.

3 Predictive Biomarker

For men with NCCN intermediate-risk cancer, this result can help determine if adding ST-ADT will be beneficial.

The ArteraAI Prostate Test is a Laboratory Developed Test that is now clinically available through a single CLIA-certified laboratory in Jacksonville, FL. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Please consult with your health care provider for personalized medical advice and determine if the ArteraAI Prostate Test is appropriate for you.